Methylone - Transcend Therapeutics
Alternative Names: TSND-201Latest Information Update: 24 Jul 2024
At a glance
- Originator Transcend Therapeutics
- Class 2 ring heterocyclic compounds; Amines; Anxiolytics; Small molecules
- Mechanism of Action Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Post-traumatic stress disorders
Most Recent Events
- 04 Apr 2024 Phase-II clinical trials in Post-traumatic stress disorders in Australia, USA (PO) (NCT06215261)
- 20 Mar 2024 Phase-I clinical trials in Post-traumatic stress disorders (In volunteers) in Australia (PO) (NCT06303648)
- 12 Mar 2024 Transcend Therapeutics plans phase-I trial for Post-traumatic stress disorders (In volunteers) in Australia (PO) (NCT06303648)